Abbott NMP22 Bladderchek Rapid Card - Pack of 10 Test (D1300E)

CE-Marked and CLIA-Waived: With the prestigious CE mark and CLIA waiver, the Abbott NMP22 BladderChek Rapid Card sets the gold standard for diagnostic reliability and user-friendliness. Trusted by healthcare professionals worldwide, it's the go-to choice for bladder cancer screening.

FDA-Cleared for Professional and Prescription Home Use: Our rapid card is not just any diagnostic tool; it's an FDA-cleared marvel designed for both professional point-of-care applications and prescribed home use in the United States. It puts the power of early diagnosis directly into the hands of healthcare providers and patients.

Detecting Bladder Cancer in At-Risk Patients: Bladder cancer doesn't discriminate, and early detection is crucial. The NMP22 BladderChek Rapid Card is a lifeline for patients at risk of bladder cancer, providing peace of mind and early intervention when it matters most.

Simple Testing Process: We've simplified the testing process to make it accessible to all. Only four drops of urine are needed to run the test, ensuring a hassle-free experience for both patients and healthcare professionals.

Rapid Results in 30 Minutes: Time is of the essence when dealing with cancer. Our rapid card provides results within 30 minutes, enabling healthcare providers to consult with patients during the same visit. It's a game-changer for immediate decision-making.

Complementing Cystoscopy for Greater Confidence: In a groundbreaking study, our NMP22 BladderChek Rapid Card proved its worth as an adjunct marker to cystoscopy. When combined with cystoscopy, it delivered a remarkable 99% sensitivity, boosting confidence in detecting recurrent cancer. It also boasted an impressive 99% NPV overall, making it the ultimate diagnostic combination for ruling out bladder cancer.

Early Detection for Early Intervention: Bladder cancer is best tackled in its early stages. The NMP22 BladderChek Test excels in early diagnosis and monitoring, working alongside standard diagnostic procedures. By detecting elevated levels of NMP22 in the urine, it identifies the presence of bladder cancer cells, even in the disease's early stages. This makes it an indispensable tool for healthcare professionals and patients alike.